Bachar Kudsieh’s research while affiliated with Hospital Universitario Puerta de Hierro-Majadahonda and other places

Purpose To report a case of early-onset blebitis following PRESERFLO® MicroShunt implantation. Patients and Methods Case report. Results A 73-year-old woman with a history of open-angle glaucoma secondary to pseudoexfoliative syndrome in her right eye underwent PRESERFLO® MicroShunt implantation augmented with mitomycin C. Three months postoperatively, she experienced ocular pain and a decrease in visual acuity. Clinical examination revealed conjunctival hyperemia surrounding a whitish filtering bleb, positive conjunctival fluorescein staining, and a positive Seidel sign leading to hypotony. Additionally, an inflammatory reaction was observed in the anterior chamber, along with localized vitreous haze. Management included topical antibiotic therapy, removal of necrotic tissue, and explantation of the PRESERFLO® MicroShunt. Staphylococcus capitis was isolated from both conjunctival and implant cultures, confirming the clinical diagnosis of infectious blebitis. Intraocular pressure and visual function were successfully restored after surgery. Conclusions Blebitis is a rare but potential complication following PRESERFLO® MicroShunt implantation with mitomycin C. Device removal may be necessary to prevent bacterial infection from extending beyond the filtering bleb into the anterior chamber.

Introduction: To analyze the role of perforating scleral vessel (PSV) and dilated choroidal veins (DCV) underneath macular myopic choroidal neovascularization (mCNV). Methods: This retrospective case-control study analyzed 78 eyes from 78 highly myopic patients defined by an axial length (AL) of ≥26 mm, assessed by optical coherence tomography (OCT) and OCT-angiography (OCTA) imaging. Patients with clinical diagnosis of mCNV and good-quality OCTA images were selected. Swept source (SS)-OCT and SS-OCTA images (TRITON; Topcon Corporation, Tokyo, Japan) were reviewed to detect image markers in the mCNV area. Highly myopic eyes without mCNV, matched by age and AL, were used as control group. The presence of PSV and DCV were recorded. Myopic maculopathy was graded using the ATN (Atrophic, Traction and Neovacularization) classification. Results: 78 eyes from 78 patients (39 with mCNV and 39 without mCNV) were included, out of the total 775 eyes screened. Fifty-nine (75.6%) of them were women. The mean ATN grading of myopic-maculopathy was compared between eyes with mCNV and those without mCNV: Atrophy scores were 2.71±0.97 vs. 2.30±0.89, respectively (p=0.04); Traction scores were 0.64±0.66 vs. 0.84±0.98, respectively (p=0.54); and Neovascularization scores were 2.00±0.00 vs. 0.33±0.73, respectively (p<0.001). The presence of OCT-imaging markers did not significantly differ between groups; i.e., PSV was found in 34/39 vs. 32/39 (p=0.53) eyes and DCV was found in 11/39 vs. 7/39 eyes, mCNV vs. control group respectively (p=0.28). Conclusions: PSV and DCV are image markers present in a high number of highly myopic eyes, which are not specific to mCNV.

Background/Objectives: To determine the impact of corneal and biometry parameters on the normative root mean square (RMS) values of corneal aberrations measured at a 6 mm diameter. Methods: The RMS values for corneal aberrations (anterior, posterior, and total) were measured along with corneal parameters using Scheimpflug tomography on 770 normal subjects. The biometric parameters were measured with an optical biometer. A multiple linear regression model was used to assess the effect of these parameters on the RMS values for corneal aberrations. Results: The mean RMS values for low-order (LOAs) and high-order 6 mm aberrations (HOAs) were 1.883 ± 0.797 µm and 0.484 ± 0.173 µm, respectively, and for the anterior and posterior cornea, the values were 0.775 ± 0.166 µm and 0.189 ± 0.036 µm, respectively. For the anterior cornea, the main predictors of the RMS LOAs (R² = 69.8%) were anterior corneal astigmatism (ACA) and anterior corneal elevation (Ele F) on the apex (both p < 0.0001) and for the RMS HOAs (R² = 33.3%) the main predictors were age, ACA, and Ele F on the thinnest point (all p < 0.0001). For the posterior cornea, considering only the posterior corneal variables, the main predictors of the RMS LOAs (R² = 63.4%) were posterior corneal astigmatism and posterior corneal elevation (Ele B) on the thinnest point and apex (all p < 0.0001) and for the RMS HOAs (R² = 46%) the main predictors were the mean posterior keratometry and Ele B on the thinnest point and apex (all p < 0.0001). Conclusions: Normative data of RMS values for corneal aberrations measured over 6 mm are influenced by age and several corneal parameters, which should be considered when evaluating the diagnostic ability of the RMS values.

The objective of this paper was to determine how different types of posterior staphyloma (PS) may affect the appearance and degree of myopic maculopathy. A cross-sectional study was conducted, in which 467 eyes from 246 highly myopic patients [axial length (AL) ≥ 26 mm] were studied. A complete ophthalmic exploration was carried out on all patients, including imaging tests. The presence of macular PS was established as the main comparison variable between groups (macular PS vs. non-macular PS vs. non-PS). The variables analyzed included age, AL, decimal best-corrected visual acuity (BCVA), Atrophy (A)/Traction (T)/Neovascularization (N) components according to the ATN grading system, and the presence of severe pathologic myopia (PM). Out of the total, 179 eyes (38.3%) presented macular PS, 146 eyes presented non-macular PS (31.2%), and 142 eyes showed no PS (30.4%). The group without PS was significantly younger than macular PS and non-macular PS groups (53.85 vs. 66.57 vs. 65.20 years; p < 0.001 each, respectively). There were no age differences between PS groups. Eyes with macular PS (31.47 ± 2.30 mm) were significantly longer than those with non-macular PS (28.68 ± 1.78 mm, p < 0.001) and those without PS (27.47 ± 1.34 mm, p < 0.001). BCVA was significantly better in the non-PS group (0.75 ± 0.27) compared to the non-macular PS (0.56 ± 0.31) and macular PS groups (0.43 ± 0.33), with p < 0.001 each. Eyes without PS showed significantly lower A and T components (1.31 ± 0.96 and 0.30 ± 0.53, respectively) than non-macular PS (2.21 ± 0.75 and 0.71 ± 0.99, respectively, p < 0.001 each) and macular PS eyes (2.83 ± 0.64 and 1.11 ± 1.10, respectively, p < 0.001 each). The N component was lower in non-PS eyes vs. non-macular PS eyes (0.20 ± 0.59 vs. 0.47 ± 0.83, p < 0.001) and as compared to the macular PS group (0.68 ± 0.90, p < 0.01). Additionally, the N component was significantly lower in the non-macular PS group than in the macular PS one (p < 0.05). The prevalence of severe PM was different between groups (p < 0.001). It was higher among macular PS eyes (138/179) when compared to other groups (p < 0.001, each), followed by the non-macular PS eyes (40/146) and being the lowest in the non-PS group (20/142). To conclude, macular PS is associated with a more advanced maculopathy, worse vision, and higher rates of severe PM.

Background: To assess the anterior scleral thickness (AST), Schlemm’s canal diameter (SCD), trabecular meshwork diameter (TMD) and conjunctiva tenon capsule thickness (CTT) in high myopic (HM) subjects and HM subjects with glaucoma (HMG) compared to control eyes. Methods: One hundred and twenty eyes were included, and AST at 0, 1, 2 and 3 mm from the scleral spur, SCD, TMD and CTT were measured. Results: Mean age was 64.2 ± 11.0 years, and the temporal SCD and temporal TMD were significantly longer in the HMG subjects compared to the controls (380.0 ± 62 μm vs. 316.7 ± 72 μm, p = 0.001) and (637.6 ± 113 μm vs. 512.1 ± 97 μm, p = 0.000), respectively. There were no significant differences between the HM and HMG subjects in SCD and TMD (all p > 0.025). Compared to the HM subjects, the temporal AST0 (432.5 ± 79 μm vs. 532.8 ± 99 μm, p = 0.000), temporal AST1 (383.9 ± 64 μm vs. 460.5 ± 80 μm, p = 0.000), temporal AST2 (404.0 ± 68 μm vs. 464.0 ± 88 μm, p = 0.006) and temporal AST3 (403.0 ± 80 μm vs. 458.1 ± 91 μm, p = 0.014) were significantly thinner in the HMG group. No differences were found between the CTT in the three groups (all p > 0.025). Conclusions: Our data indicate a thinner AST in HMG subjects and no differences in SCD and TMD between HM and HMG subjects.

Purpose: The purpose of this study is to assess the ocular dimensions of the anterior and posterior segment, including the anterior scleral thickness (AST) in nanophthalmos compared to control eyes. Methods: A cross-sectional comparative study was carried out in two groups: 46 eyes of 28 patients with nanophthalmos, defined as axial length (AXL) < 20.5 mm, and 60 eyes of 30 controls paired by age and sex. The AST and ocular wall thickness (OWT) were measured by optical coherence tomography in the temporal and nasal quadrants at 1, 2, and 3 mm from the scleral spur. Also, the anterior chamber depth (ACD), white-to-white (WTW), lens thickness (LT), subfoveal choroidal thickness (SFCT), and retinal thickness (RT) were evaluated. Results: The mean AXL was 19.3 ± 1.5 mm in the nanophthalmos group and 23.9 ± 1.1 mm in the control group (p < 0.001). The OWT was thicker in all measurement points in nanophthalmos (p < 0.001). There were no differences in the AST measurements between groups, except for the AST1 and the AST3 in the nasal quadrant. ACD was shallower and LT was thicker in nanophthalmos, with WTW being larger in controls (p < 0.001). SFCT and RT were thicker in nanophthalmos compared to healthy individuals (p < 0.001). Conclusions: Significant anatomical differences are found in nanophthalmic eyes. They present a shallower ACD; thicker LT, OWT, choroid, and retina; and smaller WTW diameter-although no relevant differences in the AST were observed.